Journal
IMMUNOLOGY
Volume 168, Issue 2, Pages 256-272Publisher
WILEY
DOI: 10.1111/imm.13562
Keywords
immunotherapy; non-small cell lung cancer; NSCLC; TME; tumour microenvironment
Categories
Ask authors/readers for more resources
This review discusses the immunotherapeutic targets in non-small cell lung cancer (NSCLC) tumors and how the tumor microenvironment (TME) can influence the response to immunotherapy.
Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of similar to 20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available